Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4RHM5)

Drug Name

Allogeneic CART-33 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Myeloid leukaemia	2B33.1	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Myeloid cell surface antigen CD33 (CD33)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gemtuzumab ozogamicin	DMJ2O7B	Acute myeloid leukaemia	2A60	Approved	[2]
Vadastuximab talirine	DM9LH10	Acute myeloid leukaemia	2A60	Phase 3	[3]
Actimab-A	DMKBIPR	Acute myeloid leukaemia	2A60	Phase 2	[3]
BI-836858	DMUVMY9	Myelodysplastic syndrome	2A37	Phase 2	[4]
Actimab-MDS	DMP8EEX	Myelodysplastic syndrome	2A37	Phase 2	[5]
GTB-3550	DMK2RIB	Acute myelogenous leukaemia	2A41	Phase 1/2	[6]
SGN-CD33A	DMRC7PI	Acute myeloid leukaemia	2A60	Phase 1/2	[7]
CART33 cells	DM81JIT	Myeloid leukaemia	2B33.1	Phase 1/2	[8]
CD33-specific gene-engineered T cells	DMM35D2	Acute myeloid leukaemia	2A60	Phase 1/2	[9]
Anti-CD33 CAR-T cells	DM9NPF6	Myeloid leukaemia	2B33.1	Phase 1/2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Myeloid cell surface antigen CD33 (CD33)	TTJVYO3	CD33_HUMAN	CAR-T-Cell-Therapy	[1]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02799680) Allogeneic CART-33 for Relapsed/Refractory CD33+ AML
2	Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin. Clin Interv Aging. 2009;4:197-205.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014 Jul;28(4):143-53.
5	Clinical pipeline report, company report or official report of Actinium Pharmaceuticals
6	Clinical pipeline report, company report or official report of GT Biopharma.
7	SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013 Aug 22;122(8):1455-63.
8	ClinicalTrials.gov (NCT01864902) Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33
9	ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
10	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies